MRNA Stock Analysis: Moderna | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 96.400m USD | 12M Return: 794.9% | US60770K1079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.18B
Qual. Beats: 1
Rev. Trend: -91.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 7.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Moderna is a biotechnology company headquartered in Cambridge, Massachusetts, that develops messenger RNA (mRNA) medicines. The mRNA platform uses synthetic nucleic acid to instruct cells to produce specific proteins, allowing a single underlying technology to be applied across vaccines, oncology, and rare disease therapeutics. Listed on NASDAQ since its December 2018 IPO, Moderna operates within the Health Care sector and is classified as a Large Cap company.
The companys portfolio spans multiple therapeutic areas. Commercial and clinical respiratory vaccines include Spikevax, mNEXSPIKE, and mRESVIA, alongside development candidates for COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccines. Additional programs target latent viruses (CMV, EBV, HIV), enteric viruses (norovirus), public health threats (Zika, Nipah, Mpox), and bacterial diseases such as Lyme. Beyond vaccines, Moderna is developing oncology therapeutics including intismeran autogene and rare disease treatments for propionic acidemia, methylmalonic acidemia, and cystic fibrosis.
Moderna operates through strategic alliances with pharmaceutical and research partners, including Merck & Co., Vertex Pharmaceuticals, immatics N.V., DARPA, BARDA, the Institute for Life Changing Medicines, the Bill & Melinda Gates Foundation, and OpenAI. Founded in 2010 as Moderna Therapeutics, the company adopted its current name in August 2018.
- Spikevax COVID vaccine revenue declines as demand normalizes post-pandemic
- mRESVIA RSV vaccine launches amid competition from Pfizer and GSK
- Merck partnership for intismeran autogene advances oncology pipeline
| Net Income: -2.79b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 7.47 > 1.0 |
| NWC/Revenue: 210.5% < 20% (prev 221.4%; Δ -10.85% < -1%) |
| CFO/TA -0.13 > 3% & CFO -1.76b > Net Income -2.79b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (430.0m) vs 12m ago 10.26% < -2% |
| Gross Margin: 28.00% > 18% (prev 11.93%; Δ 16.07% > 0.5%) |
| Asset Turnover: 19.72% > 50% (prev 18.30%; Δ 1.42% > 0%) |
| Interest Coverage Ratio: -271.2 > 6 (EBIT TTM -2.71b / Interest Expense TTM 10.0m) |
| A: 0.39 (Total Current Assets 7.34b - Total Current Liabilities 2.03b) / Total Assets 13.5b |
| B: 0.39 (Retained Earnings 5.26b / Total Assets 13.5b) |
| C: -0.21 (EBIT TTM -2.71b / Avg Total Assets 12.8b) |
| D: 1.03 (Book Value of Equity 6.84b / Total Liabilities 6.63b) |
| Altman-Z'' = 3.52 = A |
| DSRI: 0.86 (Receivables 1.37b/1.39b, Revenue 2.52b/2.22b) |
| GMI: 0.43 (GM 11.93% / 28.00%) |
| AQI: 1.15 (AQ_t 0.25 / AQ_t-1 0.22) |
| SGI: 1.14 (Revenue 2.52b / 2.22b) |
| TATA: -0.08 (NI -2.79b - CFO -1.76b) / TA 13.5b) |
| Beneish M = -3.48 (Cap -4..+1) = AA |
As of November 16, 2026, the stock is trading at USD 223.37 with a total of 8,034,922 shares traded. Over the past week, the price has changed by -12.12%, over one month by +3.29%, over three months by +250.93% and over the past year by +794.91%.
Current recommended Stop Loss: 193.00 (which is 13.6% or 1.5 ATR below the current price).
Moderna has received a consensus analysts rating of 3.09. Therefore, it is recommended to hold MRNA.
- StrongBuy: 3
- Buy: 1
- Hold: 16
- Sell: 1
- StrongSell: 2
| Analysts Target Price | 138.4 | -38.1% |
P/E Forward = 23.0415
P/S = 43.2673
P/B = 13.4893
Revenue TTM = 2.52b USD
EBIT TTM = -2.71b USD
EBITDA TTM = -2.46b USD
Long Term Debt = 590.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 52.0m USD (from shortTermDebt, two quarters ago)
Debt = 4.88b USD (from shortLongTermDebtTotal, last quarter) + Leases 696.0m
Net Debt = -296.0m USD (calculated: Debt 4.88b - CCE 5.17b)
Enterprise Value = 96.1b USD (96.4b + Debt 4.88b - CCE 5.17b)
Interest Coverage Ratio = -271.2 (Ebit TTM -2.71b / Interest Expense TTM 10.0m)
EV/FCF = -49.31x (Enterprise Value 96.1b / FCF TTM -1.95b)
FCF Yield = -2.03% (FCF TTM -1.95b / Enterprise Value 96.1b)
FCF Margin = -77.19% (FCF TTM -1.95b / Revenue TTM 2.52b)
Net Margin = -110.5% (Net Income TTM -2.79b / Revenue TTM 2.52b)
Gross Margin = 28.00% ((Revenue TTM 2.52b - Cost of Revenue TTM 1.82b) / Revenue TTM)
Gross Margin QoQ = 75.78% (prev 35.86%)
Tobins Q-Ratio = 7.14 (Enterprise Value 96.1b / Total Assets 13.5b)
Interest Expense / Debt = 0.21% (Interest Expense 10.0m / Debt 4.88b)
Taxrate = 5.26% (9.00m / 171.0m)
NOPAT = -2.57b (EBIT -2.71b * (1 - 5.26%)) [loss with tax shield]
Current Ratio = 3.62 (Total Current Assets 7.34b / Total Current Liabilities 2.03b)
Debt / Equity = 0.71 (Debt 4.88b / totalStockholderEquity, last quarter 6.84b)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -296.0m / EBITDA -2.46b)
Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -296.0m / FCF TTM -1.95b)
Total Stockholder Equity = 7.41b (last 4 quarters mean from totalStockholderEquity)
RoA = -21.79% (Net Income -2.79b / Total Assets 13.5b)
RoE = -37.62% (Net Income TTM -2.79b / Total Stockholder Equity 7.41b)
RoCE = -33.88% (EBIT -2.71b / Capital Employed (Equity 7.41b + L.T.Debt 590.0m))
RoIC = -22.71% (negative operating profit) (NOPAT -2.57b / Invested Capital 11.3b)
WACC = 9.34% (E(96.4b)/V(101b) * Re(9.80%) + D(4.88b)/V(101b) * Rd(0.21%) * (1-Tc(0.05)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 63.24 | Cagr: 5.16%
[DCF] Fair Price = unknown (Cash Flow -1.95b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.44 | # QB: 1
Revenue Correlation: -90.98 | Revenue CAGR: -34.36% | SUE: 2.08 | # QB: 1
EPS current Year (2026-12-31): EPS=-8.49 | Chg30d=-1.32% | Revisions=+0% | GrowthEPS=-17.0% | GrowthRev=+8.1%
EPS next Year (2027-12-31): EPS=-4.90 | Chg30d=-2.31% | Revisions=+22% | GrowthEPS=+42.3% | GrowthRev=+16.3%
[Analyst] Revisions Ratio: +12% (up=8, down=6)